Publisher Partnership · Multi-Therapeutic · 2026
Health Monitor Network
Equals 5 · NPI-Matched Meta Delivery · Clinician Update Powered by Personi 5™
2026 Programs
11
8 brands · 5 pharma partners
2026 Programs
11
Active · Jan–May 2026
Therapeutic Areas
4
Onc · Endo / Met · Rheum · Neuro
Latest Activation
Kisunla CU
May 4, 2026 · MCI / Early AD
NPI Match Rate
90%++
vs. 40–60% industry avg
2026 Portfolio at a Glance
HMN × Equals 5 · Clinician Update Portfolio — 2026
11
2026 Programs Active
Jan–May activations
8
Brand Programs
Novartis, Novo, Lilly, Sanofi, Daiichi Sankyo
90%++
NPI Match Rate
Industry avg: 40–60%
2.2M
Verified HCPs
Personi 5™ datagraph
48hr
Launch Speed
From signed IO to delivery
Brands by Therapeutic Area — 2026
Oncology · 3 brands · Datroway, Kisqali, Pluvicto
Endocrinology / Metabolic · 3 brands · Wegovy, Ozempic, Tzield
Rheumatology / Immunology · 1 brand · Ianalumab (3 activations)
Neurology · 1 brand · Kisunla
2026 Partnership Snapshot
Health Monitor Network · Multi-Brand CU Hub
May 13, 2026
HMN’s Clinician Update (CU) is one of the highest-engagement HCP education formats in pharma marketing — and in 2026, Equals 5 has powered every NPI-matched delivery, every physician-level engagement signal, and every monthly analytics feed across 11 programs spanning 8 brand teams at Novartis, Novo Nordisk, Eli Lilly, Sanofi, and Daiichi Sankyo.
11
2026 Programs
90%++
NPI Match Rate
8
Brand Programs
11
2026 Activations
What EQ5 Powers in 2026
For every HMN CU, Equals 5 builds the target NPI list, resolves each physician through our proprietary Personi 5™ datagraph (2.2M verified HCPs), and executes NPI-matched delivery across Meta in-feed (Facebook + Instagram) via the Health Monitor publisher page. Every impression, click, and message view is captured at the individual NPI level — with weekly sFTP delivery and monthly engagement-score reports included at no extra cost.
Why 2026 Matters for HMN
2026 expanded HMN’s partnership footprint to 5 pharma teams, added two new therapeutic franchises (Type 1 Diabetes via Tzield, Met Breast Cancer via Datroway + Kisqali), and introduced multi-format extensions for Ianalumab (CU + Podcast + Digital CU). The 90%++ NPI match rate held across every new brand and indication — proving the platform scales without diluting precision.
2026 Activation Timeline
2026 Activations — Jan to May
When each brand program signed on the EQ5 NPI-matched platform via Health Monitor.
Delivered / Active
Most Recent
2026 Programs
11 won
2026 Value
11 Programs
Most Recent
Kisunla · May 4
Platform
Personi 5™ NPI Graph
2026 Programs
Obesity / Chronic Weight Management (semaglutide 2.4mg) · Novo Nordisk
Channels: Meta in-feed · cross-brand sequencing with Ozempic NPI universe
→
Largest single 2026 activation
Program Page
View Wegovy CU
Type 2 Diabetes (semaglutide) · Novo Nordisk
Channels: Meta in-feed · sustained HCP frequency across the GLP-1 specialist universe
→
2026 renewal flight
Program Page
View Ozempic CU
Tzield CU
Type 1 Diabetes (teplizumab) · Sanofi · Two flights in 2026
Channels: Meta in-feed · T1D specialist + at-risk family medicine universe
→
New TA: Type 1 Diabetes
Program Page
View Tzield CU
Sjögren’s Disease · Novartis · CU + Podcast + Digital CU
Channels: Meta in-feed · Podcast · Digital CU — the same NPI universe activated three ways
→
Highest format diversity
Program Page
View Ianalumab
Kisqali CU
Metastatic Breast Cancer (ribociclib) · Novartis
Channels: Meta in-feed · Shared mBC universe with Datroway
→
Cross-brand mBC sequencing eligible
Program Page
View Kisqali CU
Datroway CU
Metastatic Breast Cancer (datopotamab deruxtecan) · Daiichi Sankyo
Channels: Meta in-feed · First Daiichi Sankyo activation via HMN
→
New pharma partner: Daiichi Sankyo
Program Page
View Datroway CU
Metastatic Prostate Cancer / mCRPC (lutetium Lu 177) · Novartis
Channels: Meta in-feed · Dual-audience strategy across treaters and referrers
→
Treaters + Referrers strategy
Program Page
View Pluvicto CU
MCI / Early Alzheimer’s Disease (donanemab) · Eli Lilly · Branded Clinician Update
Channels: NPI-Matched Meta in-feed (Facebook + Instagram) via Health Monitor publisher page
→
Most recent 2026 signing
Program Page
View Kisunla CU
Audience Architecture
NPI Match Rate
90%++
Personi 5™ deterministic matching · vs. 40–60% industry avg
Verified HCP Universe
2.2M
Full specialty coverage across all HMN TAs
Therapeutic Areas (2026)
4
Onc · Endo / Met · Rheum · Neuro
NPI Match Rate — HMN CU vs. Industry
Personi 5™ deterministic matching delivers 1.5× the industry baseline
Channels & Execution
2026 Programs by Pharma Partner
11 programs across 5 partners
2026 Programs by Therapeutic Area
Activation count · Jan–May 2026
NPI-Matched Meta (Facebook + Instagram)
Primary HCP Delivery
All 11 CU programs · Health Monitor publisher page
Personi 5™ Datagraph
NPI Identity Infrastructure
2.2M verified HCPs · deterministic NPI matching
Clinician Update Format
7-message Peer-Led Education
HMN proprietary editorial format · individual destination URLs
Podcast & Digital CU Extensions
Format Diversification (Ianalumab)
Same NPI universe · multi-format engagement signals
NPI-Level Reporting
Measurement & Attribution
Weekly sFTP · Monthly NPI engagement report
Engagement Scoring
Physician-Level Intent Data
Cold → Aware → Warm → Hot Lead → MSL Ready
Tier 1
MSL Ready / Hot Lead
Multi-message engagement · HCPs flagged for field follow-up
Tier 2
Warm / Aware
NPI-confirmed clicks · retargeting candidates
Tier 3
Cold Reach
First-impression cohort · awareness foundation
Measurement & Reporting
Upcoming & In-Planning
Apitegromab CU — Spinal Muscular Atrophy
Neuromuscular specialist audience · Rare Disease
In Planning
Rare-disease activation for SMA — small specialist universe (neuromuscular and pediatric neurology) where full-universe NPI coverage is the lead value proposition. Timeline confirming for H2 2026.
Next step: Scope confirmation · flight window
Wegovy + Ozempic — H2 2026 Renewal Window
Novo Nordisk GLP-1 portfolio extension
Renewal Window
Both flagship GLP-1 programs activated in January; H2 renewal conversations open in Q3. Cross-brand sequencing across the shared endocrinology universe is the lead expansion angle.
Next step: Mid-flight performance review · H2 IO
2026 Program Timeline
⚖️
Wegovy CU — Flagship Activation
Largest 2026 single activation · Jan 16
View program details ›
🧠
Kisunla CU — Newest Activation
MCI / Early AD · activated May 4, 2026
View program details ›
H2 2026 — Apitegromab CU
SMA rare-disease activation in planning
Q3 2026 — GLP-1 Renewal Window
Wegovy + Ozempic mid-flight review
Ongoing — All 11 programs delivering
Weekly NPI-level reporting active
Oncology
Datroway · Kisqali · Pluvicto
Endo / Metabolic
Wegovy · Ozempic · Tzield
Rheum / Immunology
Ianalumab (3 formats)
Neurology
Kisunla
Therapeutic Coverage
4 TAs
Every HMN CU runs on a single unified NPI-matched platform with shared identity infrastructure — cross-brand sequencing within a TA (Ozempic ↔ Wegovy, Datroway ↔ Kisqali) is available at no incremental list cost.